Saratoga Aggressive Balanced Allc I holds a quantitatively derived Negative Morningstar Medalist Rating. The rating indicates the model sees limited potential for the strategy to outperform peers on a risk-adjusted basis over a full market cycle.
Saratoga Aggressive Balanced Allocation Portfolio Class I SABIX
- NAV / 1-Day Return 12.76 / +0.71 %
- Total Assets 1.8M
-
Adj. Expense Ratio
2.280%
- Expense Ratio 0.990%
- Distribution Fee Level High
- Share Class Type Institutional
- Category Moderately Aggressive Allocation
- Investment Style Mid Blend
- Credit Quality / Interest Rate Sensitivity Medium/Moderate
- Status Open
- TTM Yield 2.25%
- Turnover 3%
USD | NAV as of Oct 03, 2026 | 1-Day Return as of Oct 03, 2026, 12:22 AM GMT+0
Morningstar’s Analysis SABIX
Will SABIX outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 92.4
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Saratoga Large Capitalization Growth I | 15.58 | 287,521 | — |
Vanguard Interm-Term Bond Index Adm | 14.96 | 276,050 | — |
Saratoga Large Capitalization Value I | 13.70 | 252,758 | — |
Saratoga Mid Capitalization I | 13.01 | 239,998 | — |
Saratoga Small Capitalization I | 10.43 | 192,369 | — |
Vanguard Total Intl Stock Index Admiral | 8.44 | 155,758 | — |
BNY Dreyfus Instl Pref Govt MMkt Instl | 7.57 | 139,709 | Cash and Equivalents |
Saratoga Technology & Comm I | 6.83 | 125,998 | — |
Eaton Vance Glbl Macr Absolute Return I | 3.93 | 72,552 | — |
Saratoga Health & Biotechnology I | 3.68 | 67,982 | — |